New York Times Examines Generic Drugs' Path To FDA Approval
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Public Health
Article Date: 27 Feb 2006 - 11:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
The New York Times on Thursday examined recent criticism that FDA "is falling behind in its review of generic drug applications" and profiled the approval this week of a generic version of the allergy nasal spray Flonase. According to the Times, FDA currently has a backlog of more than 850 applications for generic medications, compared with 320 in 2001. The Bush administration has proposed no budget increase for the FDA Office of Generic Drugs, which reviews applications for generic medications, but several members of a House appropriations subcommittee have suggested to acting agency Commissioner Andrew von Eschenbach that Congress might increase the budget for the office. Kathleen Jaeger, president and CEO of the Generic Pharmaceutical Association, has said that the federal government would have to spend only an additional $15 million annually to eliminate the backlog. Scott Gottlieb, FDA deputy commissioner for medical and scientific affairs, last week also suggested that user fees from generic pharmaceutical companies could help reduce the backlog. Generic pharmaceutical companies have said that they would consider the fees, provided FDA addresses "unintended loopholes and regulatory abuses" that delay the approval of their products, according to Jaeger. However, FDA "has little control over some delaying factors, including the patenting of many aspects of a drug's manufacture and use," and "Flonase is a case in point," the Times reports. Prior to approval of the generic version, GlaxoSmithKline, which manufactures Flonase, filed two "citizen petitions" to request that FDA reconsider different areas of the review process, and others also filed at least two such petitions. The petitions required FDA to respond after consideration and delayed approval of the generic version of Flonase (Harris, New York Times, 2/23).
"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/38331.php>
APA
http://www.medicalnewstoday.com/releases/38331.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



